MedTrace Logo

VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine

NCT04130282 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2020-09-29

No results posted yet for this study

Summary

This is an open label, single-site, first-in-human, Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs25-IMX313 in Matrix-M1 adjuvant in healthy adults living in the UK

Volunteers will receive 3 doses of vaccine over 2 months and will be followed up for approximately 8 months.

Conditions

  • Malaria,Falciparum

Interventions

BIOLOGICAL

Pfs25-IMX313/Matrix-M1

3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Angela Minassian, PhD · University of Oxford

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-27
Primary Completion
2020-09-22
Completion
2020-09-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04130282 on ClinicalTrials.gov